Brit J Cancer:高度和体重指数与BRCA1和BRCA2突变携带者卵巢癌风险

2019-06-23 xing.T MedSci原创

由此可见,我们观察BMI与绝经前BRCA1/2突变携带者卵巢癌风险之间存在正相关,这与一般人群中的结果一致。

身高和体重指数(BMI)与一般人群中较高的卵巢癌风险相关,但BRCA1/2突变携带者之间是否存在这种关联尚不清楚。

近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员使用应用孟德尔随机化方法使用BRCA1/2研究者协会(CIMBA)数据集评估身高/BMI与卵巢癌风险,纳入了14676名BRCA1和7912名BRCA2突变携带者,以及2923例卵巢癌病例。研究人员使用了586名BMI相关变异体创建了身高遗传评分(身高-GS),以及使用96名BMI相关变异体创建了BMI遗传评分(BMI-GS),并使用加权Cox模型评估关联。

研究人员观察到身高与卵巢癌风险无关(身高每增加10厘米的风险比[HR]:1.07,95%置信区间[CI]:0.94-1.23)。高度-GS得到相似的结果(HR=1.02,95%CI:0.85-1.23)。较高的身高与绝经前女性卵巢癌风险增加相关(观察到的和遗传决定的BMI每增加5kg/m2,分别有HR=1.25(95%CI:1.06-1.48)和HR=1.59(95%CI:1.08-2.33)。在绝经后女性中没有观察到这种关联。绝经状态与BMI之间的相互作用是显著的(相互作用P<0.05)。

由此可见,我们观察BMI与绝经前BRCA1/2突变携带者卵巢癌风险之间存在正相关,这与一般人群中的结果一致。

原始出处:

Frank Qian.et al.Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 andBRCA2 mutation carriers.British Journal of Cancer.2019.https://www.nature.com/articles/s41416-019-0492-8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-04-03 yige2014
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2020-03-06 qblt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-11-17 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-25 njwbhuang

    好文章,感谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-25 智智灵药
  7. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-25 TZF0810
  8. [GetPortalCommentsPageByObjectIdResponse(id=1715654, encodeId=50651e1565463, content=<a href='/topic/show?id=e5893694bc' target=_blank style='color:#2F92EE;'>#BRCA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3694, encryptionId=e5893694bc, topicName=BRCA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2531999527, createdName=yige2014, createdTime=Fri Apr 03 19:33:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004927, encodeId=f425200492efd, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Mar 06 06:33:00 CST 2020, time=2020-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061853, encodeId=0939206185359, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Sun Nov 17 22:33:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368326, encodeId=0cca368326fd, content=好文章,感谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jun 25 13:17:06 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423307, encodeId=be0f142330e11, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594043, encodeId=81b91594043cd, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602849, encodeId=2e66160284970, content=<a href='/topic/show?id=e0b5393680' target=_blank style='color:#2F92EE;'>#CA2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3936, encryptionId=e0b5393680, topicName=CA2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03ab18968787, createdName=TZF0810, createdTime=Tue Jun 25 04:33:00 CST 2019, time=2019-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368263, encodeId=0d2336826355, content=BRCA1/2突变携带者之间是否存在这种关联尚不清楚。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Mon Jun 24 09:18:15 CST 2019, time=2019-06-24, status=1, ipAttribution=)]
    2019-06-24 cqykthl

    BRCA1/2突变携带者之间是否存在这种关联尚不清楚。

    0

相关资讯

病床,调高还是调低?

这样的细节,你是否思考过?